Urol. praxi, 2013; 14(4): 152-156

Advanced prostate cancer and new drugs from medical oncologist’s point of view

MUDr.Hana Študentová1, MUDr.Vladimír Študent jr.2, doc.MUDr.Vladimír Študent, Ph.D.2, prof.MUDr.Bohuslav Melichar, Ph.D.1
1 Onkologická klinika, Fakultní nemocnice, Olomouc, 2Urologická klinika LF UP a FN OLomouc

There were several new agents for treatment of advanced prostate cancer registered in Europe in past few years such as abiraterone

acetate, enzalutamide and cytotoxic agent cabazitaxel. Because of the new drugs, novel approaches and knowledge of disease pathogenesis

we are capable not only to improve patient´s quality of life but also prolong it significantly.

Keywords: advanced prostate cancer, abiraterone acetate, enzalutamide, cabazitaxel

Published: October 27, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Študentová H, Študent V, Študent V, Melichar B. Advanced prostate cancer and new drugs from medical oncologist’s point of view. Urol. praxi. 2013;14(4):152-156.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Tewari A, Raman JD, Chang P, et al. Long-term survival probability in men with clinically localized prostate cancer treated either consevatively or with definitive treatment (radiotherapy or radical prostatectomy). Urology 2006; 68(6): 1268-1274. Go to original source... Go to PubMed...
    2. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patiens with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26 (7): 1148-1159. Go to original source... Go to PubMed...
    3. NCCN Guidelines Version 2. 2013.
    4. Sher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197. Go to original source... Go to PubMed...
    5. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl. J Med 2013; 368: 138-148. Go to original source...
    6. Fizazi K, Scher H, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983-992. Go to original source... Go to PubMed...
    7. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512. Go to original source... Go to PubMed...
    8. Armstrong AJ, Garrett-Mayer E, De WitR, Tannock I, Eisenberger M. Prediction of survival following first-line chemotherapy in men with castratin-resistant metastatic prostate cancer. Clin Cancer Res. 2010; 16: 203-211. Go to original source... Go to PubMed...
    9. Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patiens with prostate cancer. Eur J Cancer. 2010; 46: 1770-1772. Go to original source... Go to PubMed...
    10. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154. Go to original source... Go to PubMed...
    11. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363(5): 411-422. Go to original source... Go to PubMed...
    12. Bartůňková J, Špíšek R, Podrazil M. Imunoterapie karcinomu prostaty. Urol. praxi, 2013; 14(1): 15-18.
    13. Fučíková J, et al. Human tumor cells killed by anthracyclines induce a tumor-specific imunne response. Cancer Res. 2011; 71(14): 4821-4833. Go to original source... Go to PubMed...
    14. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zolendronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822. Go to original source... Go to PubMed...
    15. Sartor OA, Heinrich D, Helle SI, et al. Radium-223 chloride impact on the skeletal-related events in patiens with castration resistant prostate cancer (CRPC) with bone metastases. A phase III randomised trial (ALSYMPCA). Proc Am Soc Clin Oncol 2012; 30(Suppl 5): Abstract 9. Go to original source...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.